COPD activates bitter taste receptors, the target of asthma treatment

Published Date: 17 Mar 2023

Germany: Activation of bitter taste receptors opens lung pathways, making them potential targets for the treatment of chronic lung diseases...

Read Full News

Latest News

Asthma in 2025: Year in Review

Asthma in 2025: Year in Review

COPD in 2025: Year in Review

COPD in 2025: Year in Review

Characterizing COPD - Lung Cancer Patients, with Joseph Friedberg, MD Joseph Friedberg, MD, Kevin Kunzmann

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

Todays Updates

Uncovering the Complex Relationship Between ADHD and Epilepsy Surgery Outcomes Marco Meglio

Janelle Wagner, PhD, a clinical psychologist and research professor at the Medical University of South Carolina, provided clinical insights on a recently presented study on whether elevated ADHD symptoms impact post epilepsy surgery seizure freedom.

This Week on NeurologyLive® — January 5, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

AI Model Distinguishes EDSS Subgroup Patterns in Multiple Sclerosis, Study Shows Louie Pasculli

A new large-scale analysis revealed that patients with identical EDSS scores can exhibit distinct patterns of functional impairment, identified using artificial intelligence–based clustering algorithms.

Rheumatology in 2025: Year in Review

Rheumatology in 2025: Year in Review

Early Week 2 Response Predicts Sustained Benefit with Adjunct Cariprazine in MDD

Early Week 2 Response Predicts Sustained Benefit with Adjunct Cariprazine in MDD

KDIGO Releases New Guideline for Anemia in Chronic Kidney Disease

KDIGO Releases New Guideline for Anemia in Chronic Kidney Disease

Chronic Kidney Disease Paired With Social Frailty May Increase Depression Risk

Chronic Kidney Disease Paired With Social Frailty May Increase Depression Risk

Todays Updates

Uncovering the Complex Relationship Between ADHD and Epilepsy Surgery Outcomes Marco Meglio

Janelle Wagner, PhD, a clinical psychologist and research professor at the Medical University of South Carolina, provided clinical insights on a recently presented study on whether elevated ADHD symptoms impact post epilepsy surgery seizure freedom.

This Week on NeurologyLive® — January 5, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

AI Model Distinguishes EDSS Subgroup Patterns in Multiple Sclerosis, Study Shows Louie Pasculli

A new large-scale analysis revealed that patients with identical EDSS scores can exhibit distinct patterns of functional impairment, identified using artificial intelligence–based clustering algorithms.

Rheumatology in 2025: Year in Review

Rheumatology in 2025: Year in Review

Early Week 2 Response Predicts Sustained Benefit with Adjunct Cariprazine in MDD

Early Week 2 Response Predicts Sustained Benefit with Adjunct Cariprazine in MDD

KDIGO Releases New Guideline for Anemia in Chronic Kidney Disease

KDIGO Releases New Guideline for Anemia in Chronic Kidney Disease

Chronic Kidney Disease Paired With Social Frailty May Increase Depression Risk

Chronic Kidney Disease Paired With Social Frailty May Increase Depression Risk

Latest News

Asthma in 2025: Year in Review

COPD in 2025: Year in Review

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

News All Time

Rewriting Airway Disease With Trait-Based Care: 2025’s Convergence of Asthma and COPD Management

Rewriting Airway Disease With Trait-Based Care: 2025’s Convergence of Asthma and COPD Management

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

How to Set a Biologic Strategy for Asthma, with Sara Assaf, MD Sara Assaf, MD

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Lungcast: Resilience and Sustainability: Preparing Healthcare for the Future with Elizabeth Cerceo, MD Albert Rizzo, MD, Elizabeth Cerceo, MD

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

Long-Term Data Support New Zopapogene Imadenovec Approval for RRP Victoria Johnson

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

Nerandomilast Approval Breaks Decade-Long Dry Spell for IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

Mucoactives Found to Have Little Benefit for Bronchiectasis Victoria Johnson

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

FDA Accepts NDA for Chiesi’s Single Inhaler Triple Therapy for Asthma Victoria Johnson

The therapy is currently approved in almost 50 countries under the name Trimbow.

FDA Approval Adds Tezepelumab to CRSwNP Treatment Landscape Victoria Johnson

Tezepelumab is the first TSLP-targeting biologic to be approved for chronic rhinosinusitis with nasal poylps.

Sleep Apnea Significantly Impacts Mortality Benefit of GLP-1s Kevin Kunzmann

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

4 Trials That May Change Pulmonary Embolism, with Parth Rali, MD Parth Rali, MD

Rali highlights a series of randomized, controlled trials that could reinvigorate the recently stagnant field of PE treatment development.

Redefining Severe Airway Disease Care: Clinicians Weigh In on Biologics and Barriers Victoria Johnson

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

The Case for More Spirometry, Pulmonary Function Testing, with Meredith McCormack, MD Kevin Kunzmann

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

Dupilumab, Tezepelumab Provide Consistent Real-World Severe Asthma Outcomes Kevin Kunzmann

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.

Opportunities to Define and Treat Indoor Air Quality, with Sarath Raju, MD, MPH Sarath Raju, MD, MPH

Most clinicians are not considering poor home air exposure when treating persistent asthma or airway disease, Raju explains. That may be making a difference in outcomes.

Recommended News For You

Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study

'Ticking Time Bomb'; Jimmy Carter's Lasting Impact on Cancer; Breast Cancer-CVD Link

Non-Hodgkin lymphomas that are indolent have been linked to psychological distress.

Pancreatic Cancer: A Novel CD40 Agonist-Chemo Combo Shows Promise.

Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer

Cancer After Weight Loss; How Older Adults Use the Healthcare System.

the contribution of cortactin to the development of cancer.

Recommended Articles For You

Unleashing Precision Medicine: CRISPR-Cas9 Gene Editing in Hematopoietic Stem Cells 

Understanding Hidrocystoma: Symptoms, Causes, and Treatment Options  

Bispecific Antibodies in DLBCL & Myeloma: Clinical Insights for Physicians 

The Bloodstream Compass: A Comparative Clinical Review of Liquid Biopsy and AI in Predictive Oncology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How to keep your prostate healthy and lower your risk of developing serious problems

2.

Treatment of Smoldering Myeloma Cuts Progression Rate in Half

3.

PSA Testing Is Not Enough for Another Candidate for Prostate Cancer Screening.

4.

AI is useful in low-resource areas for triaging breast masses.

5.

Can Prior Authorization Be Better With Artificial Intelligence?

1.

RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health 

2.

What Is A High MCV Level? Causes, Symptoms, And Treatment Options

3.

Revolutionizing Oncology: AI in Radiology, Machine Learning in Pathology, and Deep Learning for Cancer Detection

4.

Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025

5.

7 Subtle Signs of Leukemia: How to Spot the Symptoms Early

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

2.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI

3.

Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion

4.

Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.

5.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot